Ipamorelin research, organized by what each study actually measured

Before the details

Ipamorelin research splits into a few clean buckets. First, the founding study that proved selectivity — releasing growth hormone (GH) without the stress hormones. Second, the pharmacokinetics: how the body absorbs and clears it, including the one solid human dataset. Third, the disappointing clinical trial for slow bowel recovery after surgery. Fourth, the animal work on bone growth and recent cachexia (wasting) models. And fifth, a body of mechanism studies explaining why you can stack ipamorelin with a different kind of GH-releasing peptide for a bigger effect. Every quantitative claim below maps to a numbered source. Jargon is glossed the first time it appears, so you can read straight through without a biochemistry background.

The selectivity mechanism: GH without the side channels

The defining ipamorelin study released GH potently in primary rat pituitary cells, anaesthetised rats, and conscious swine, with a swine ED50 of 2.3 ± 0.03 nmol/kg versus 3.9 nmol/kg for GHRP-6 ^[1]. The breakthrough was what stayed flat: ACTH and cortisol did not rise above the GHRH baseline even at doses more than 200 times the GH ED50 ^[1]. That is the entire selectivity claim, and it is the reason ipamorelin became the reference compound for 'clean' GH release.

Mechanistically, ipamorelin is a selective agonist of GHS-R1a — the ghrelin / growth hormone secretagogue receptor — on pituitary somatotrophs (the GH-producing cells). Binding there triggers a Gq/PLC cascade that raises intracellular calcium and drives GH out of the cell ^[1]. A fish-pituitary study added a useful mechanistic detail: ipamorelin (with GHRP-2) released GH from black seabream pituitary cells in the nanomolar range without changing GH gene transcription even at 48 hours ^[11], showing the GHS-R mechanism acts at the secretory level — it releases stored hormone rather than telling the cell to make more.

Human pharmacokinetics: one clean pulse, ~2-hour half-life

The human PK/PD study remains one of the only human ipamorelin datasets. In healthy male volunteers (n=8 per dose level) given five 15-minute intravenous infusions of 4.21 to 140.45 nmol/kg, the kinetics were dose-proportional with a terminal half-life of approximately 2 hours, clearance of 0.078 L/h/kg, and a steady-state volume of distribution of 0.22 L/kg ^[2]. The GH response was a single discrete pulse peaking at about 0.67 hours — roughly 40 minutes — after dosing ^[2]. The mirror of a natural GH pulse, produced on cue, is exactly the pharmacology that made ipamorelin attractive.

Does cjc-1295 ipamorelin work — and the synergy that explains the stack

Whether the popular combination 'works' depends entirely on what you ask of it. There is no controlled human trial of CJC-1295 plus ipamorelin for any outcome — the combination's rationale rests on single-agent pharmacology and a well-established physiological synergy, not on combination efficacy data. What the literature does establish is the synergy itself. In rats neutralized of endogenous GHRH and somatostatin, exogenous GHRH plus a GHRP produced GH peaks significantly greater than the sum of the individual peaks — a genuinely synergistic, more-than-additive response ^[12]. GHRP-6 activity was attenuated by GHRH antiserum or GHRH-receptor blockade, proving endogenous GHRH is required for full GHRP-induced GH release ^[13]. In GHRH-knockout mice, a GHRH analog plus GHRP-2 produced greater body length and weight than the analog alone, and GHRP-2 alone failed to stimulate GH at all ^[14]. An ovine pituitary study supplied the molecular basis: combined GHRH and GHRP-2 upregulated GH mRNA, GHS-R, GHRH-R, and Pit-1, while GHRP-2 suppressed both somatostatin-receptor subtypes ^[15]. Together these explain why pairing a GHRH analog with a GHS-R1a agonist amplifies GH — the two pathways are complementary by design.

What is cjc 1295 ipamorelin

It is a two-peptide research combination, not a single molecule. CJC-1295 is a GHRH analog — it mimics growth-hormone-releasing hormone and acts on the GHRH receptor through a cAMP pathway. Ipamorelin is a GHS-R1a (ghrelin-receptor) agonist that acts through a separate calcium pathway ^[1]. Because the two receptors drive GH release by complementary mechanisms, their combined effect is synergistic rather than merely additive ^[12]. The combination is studied and discussed only as research material; it has no controlled human efficacy trial and no regulatory approval.

Ipamorelin cjc-1295

The pairing of ipamorelin cjc-1295 is the most-searched ipamorelin topic, and the science behind it is the GHRH-plus-GHRP synergy described above. CJC-1295 supplies sustained GHRH-receptor tone; ipamorelin supplies a clean, selective GHS-R1a pulse ^[1]. Animal work shows the combination of a GHRH signal and a GHRP signal produces GH release exceeding the sum of the parts ^[12], with genetic-model confirmation that GHRH presence is a prerequisite for the GHRP to work at all ^[14]. None of this is combination efficacy data in humans — it is the mechanistic foundation that the combination is built on.

Bone, body composition, and the most recent in-vivo data

Subcutaneous ipamorelin at 18, 90, and 450 micrograms per day (divided three times daily for 15 days) dose-dependently raised the longitudinal bone growth rate of adult female rats from 42 micrometers per day in vehicle controls to 44, 50, and 52 micrometers per day, with no change in total IGF-1, IGFBPs, or bone turnover markers ^[4]. The absence of an IGF-1 change points to a partly local, GH-pulse-driven skeletal effect.

The freshest published in-vivo finding is the 2024 ferret study: intraperitoneal ipamorelin (1 to 3 mg/kg) inhibited cisplatin-induced body-weight loss by about 24% on the last day of the delayed phase, though it had no anti-emetic effect on either acute or delayed emesis ^[5]. Ipamorelin has also been used as the lead scaffold for medicinal-chemistry programs — analogs derived from it achieved oral bioavailability of 10 to 55% in dogs while retaining intravenous potency in swine ^[8], with hybrid and conformationally restricted derivatives reaching low-nanomolar GHS-R1a potency ^[9][10] — work that maps the structural rules governing this peptide class.

Ipamorelin vs sermorelin

Ipamorelin vs sermorelin is a comparison of two different receptor families. Sermorelin is a GHRH analog (the active 1–29 fragment of growth-hormone-releasing hormone) that works on the GHRH receptor. Ipamorelin is a GHS-R1a (ghrelin-receptor) agonist that works on a separate receptor and pathway ^[1]. They are mechanistic complements rather than alternatives — which is precisely why GHRH analogs and GHS-R1a agonists are combined, given the more-than-additive GH response when both pathways are engaged ^[12]. This site documents ipamorelin specifically; sermorelin's own clinical record is separate.

Ipamorelin vs tesamorelin

Ipamorelin vs tesamorelin is, again, a GHS-R1a agonist versus a GHRH analog. Tesamorelin is a stabilized GHRH analog with its own distinct regulatory history. Ipamorelin acts on the ghrelin receptor through a calcium-driven mechanism and is defined by its selectivity — releasing GH without raising cortisol or prolactin ^[1]. The two engage different receptors and would, on the mechanistic logic of GHRH-plus-GHRP synergy, be complementary rather than interchangeable ^[12]. The comparison most often sought online is about receptor mechanism and selectivity, not a head-to-head efficacy trial, of which none exists for ipamorelin.